Company Overview
About HeartFlow
HeartFlow, Inc. is a Redwood City, California–based medical technology company founded in 2011 that applies artificial intelligence to cardiac imaging to transform the diagnosis and management of coronary artery disease (CAD). Its flagship HeartFlow FFRCT Analysis generates a personalized, color-coded 3D model of a patient's coronary arteries from a standard CT scan, calculating fractional flow reserve values non-invasively to identify which blockages actually restrict blood flow. The technology is backed by more than 600 peer-reviewed publications and has helped clinicians manage over 400,000 patients worldwide.
Business Model & Competitive Advantage
In 2025, HeartFlow significantly expanded its clinical and commercial footprint. The company received FDA 510(k) clearance for its next-generation Heartflow Plaque Analysis platform in September 2025, which quantifies coronary plaque burden and composition to stratify cardiovascular risk beyond what anatomical imaging alone can detect. The American College of Cardiology and American Heart Association published scientific statements supporting plaque analysis as a defined clinical consideration in CAD management, and Cigna extended coverage for the technology effective October 2025.
Competitive Landscape 2025–2026
HeartFlow completed a $364 million IPO on the Nasdaq Global Market under ticker symbol HTFL in August 2025, providing capital to accelerate commercial expansion and international adoption. The company's DECIDE Registry data, presented at AHA 2025, showed that HeartFlow Plaque Analysis changed medical management in more than half of patients beyond CT angiography alone, reinforcing the platform's clinical utility across the full coronary care pathway.
Key Differentiators
Strong Challenger
HeartFlow is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Compare HeartFlow with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from HeartFlow? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim HeartFlow Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention HeartFlow vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →